Biocon Biologics announced last week that they received FDA approval for a new biosimilar version of insulin aspart which they have dubbed Kirsty (insulin aspart-xjhz). The FDA has granted Biocon Biologics the interchangeability designation for automatic substitution with the reference product NovoLog. Biocon Biologics first applied for approval of this product in July 2020. The … Continue reading After Five-Year Journey, Biocon Biologics Obtains a New Approval for Insulin Aspart Biosimilar